Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients.

ABSTRACT:

Background

Hypertensive haemodialysis patients may be at a high risk for cardiovascular events. This study was undertaken to ascertain whether the calcium channel blocker amlodipine reduces mortality and cardiovascular events in these high-risk patients.

Methods

We evaluated the effects of amlodipine on cardiovascular events in 251 hypertensive haemodialysis patients in an investigator-designed, prospective, randomized, double-blind, placebo-controlled, multicenter trial. One hundred and twenty-three patients were randomly assigned to amlodipine (10 mg once daily) and 128 to placebo. The primary endpoint was mortality from any cause. The secondary endpoint was a composite variable consisting of mortality from any cause or cardiovascular event. Analysis was by intention-to-tr

SUBMITTER: Tepel M 

PROVIDER: S-EPMC2568006 | biostudies-literature | 2008 Nov

REPOSITORIES: biostudies-literature